Press Release

FOR IMMEDIATE RELEASE CONTACT: Paul Roth

March 3, 2010 (213) 283-6570

AVT-12 WEIGHT LOSS DRUG PRODUCT STUDY CONCLUDES

Los Angeles, CA, March 3 -- The weight loss combination drug product, AVT-12 has
most recently been the subject of a year-long phase III randomized, double-blind,
placebo-controlled efficacy trial, conducted by ITCES Corporation.

Discovered by Stanford University School of Medicine in 2005, obestatin has repeatedly

demonstrated an ability to positively modify certain natural overfeeding behaviors which
contribute to obesity.

AVT-12 is thought to improve GPR39 G protein-coupled receptor affinity to obestatin

Zn(2+) and associated peptides shown effective in weight loss. Importantly, the natural
serum levels of obestatin are not altered.

Through improving GPR39 receptor affinity, rather than increasing total levels of
obestatin, negative feedback compensation is reduced, contributing to marked
improvements in long-term outcome. In brief:

Mean Value Weight Weight Weight Loss Weight Loss BMI

(kg) (lbs) (lbs) (%) (kg/m2)
Baseline
AVT-12 Group 98.2 216.0 - - 35.9
Placebo Group 97.8 215.2 - - 36.1
12 Months
AVT-12 Group 70.5 155.1 60.9 39.3% 25.8
Placebo Group 94.6 208.1 7.1 3.4% 34.9

About ITCES:

ITCES Corporation partners with innovators to evaluate and develop applied

biotherapeutics from concept to market. ITCES delivers timely value to clients by
facilitating and analyzing critical research, while protecting intellectual property.

###
Contact:
Paul Roth
Asst. Public Affairs Director
ITCES Corporation
(213) 283-6570
http://AVT12.info